[Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
A patient with advanced multiple myeloma (MM) and renal failure presented a severe chronic anemia requiring frequent blood transfusions. Treatment with recombinant human erythropoietin (rHuEPO) led to a rapid improvement of anemia, and further blood transfusions were not required. Pathophysiological studies about the erythropoiesis in patients with MM and trials with rHuEPO in myeloma-associated anemia are commented.
Arenas Gracia
M
M
Servicio de Medicina Interna, Hospital General de Area de Elda, Alicante.
Abad Gosálvez
A
A
Colomina Avilés
J
J
Pascual Pérez
R
R
Ferriz Moreno
P
P
D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004921:Erythropoietin / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007145:Immunoglobulin kappa-Chains; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D009101:Multiple Myeloma / Q000150:complications* / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use
D007145:Immunoglobulin kappa-Chains; D011994:Recombinant Proteins; D004921:Erythropoietin